NCT03390322View on ClinicalTrials.gov

Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients

NACompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions

Diabetes Mellitus, Type 2

Interventions

DEVICE

DiaGone™

Duodenal Glycemic Control™ using the DiaGone™ system

Trial Locations (3)

Unknown

IKEM, Prague

Soroka Medical Center, Beersheba

Shaarei Tzedek, Jerusalem

Sponsors

Lead Sponsor

Digma Medical Ltd.

All Listed Sponsors

lead

Digma Medical Ltd.

INDUSTRY

NCT03390322 - Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter